Growth-differentiation factor-15 and tissue doppler imaging in detection of asymptomatic anthracycline cardiomyopathy in childhood cancer survivors

Basit Öğe Kaydı
dc.contributor.authorArslan, Derya
dc.contributor.authorCihan, Tugba
dc.contributor.authorKose, Dogan
dc.contributor.authorVatansev, Husamettin
dc.contributor.authorCimen, Derya
dc.contributor.authorKoksal, Yavuz
dc.contributor.authorOran, Bulent
dc.date.accessioned2020-03-26T18:42:05Z
dc.date.available2020-03-26T18:42:05Z
dc.date.issued2013
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractObjectives: Anthracyclines have led to an increased risk of cardiac morbidity and mortality. Late cardiac complications in cancer survivors may develop from subclinical myocardial damage. Tissue Doppler imaging (TDI) also has potential as a clinically useful technique for the assessment of myocardial function. Biochemical markers may be used to detect cardiac damage growth-differentiation factor-15 (GDF-15) and are emerging as a biomarker of cardiac dysfunction. The aim of this study is to assess the value of the plasma levels of GDF-15 and TDI in detecting late myocardial dysfunction in childhood cancer survivors (CCS) who were treated with anthracyclines. Design and methods: Thirty-eight CCS who had completed chemotherapy treatment with anthracyclines were included in this study. Control group consisted of 32 age- and gender-matched healthy volunteers. All children underwent a detailed echocardiography, which contained an M-mode, pulse Doppler and tissue Doppler imaging. However, GDF-15 and cardiac troponin-I (cTnI) were measured. Results: Although, systolic function of the left ventricular was similar in all groups, there were significant differences between parameters of diastolic function of the heart. The mitral valve E wave, E/A ratio, left ventricular E'm wave, and E'm/A'm ratio were different in the patients than in the controls (p = 0.049, p = 0.037, p < 0.0001, p = 0.001, respectively). The tricuspid valve E/A ratio, right ventricular E't wave, and E't/A't ratio in the patients were also different from those of the controls (p = 0.031, p < 0.0001, p < 0.0001, respectively). Mean plasma GDF-15 was significantly higher in patients than healthy controls (p = 0.027). There were no significant differences in cTnI between both groups. Conclusions: Growth-differentiation factor-15 level may be used as a biomarker of anthracycline-induced cardiovascular disease severity in the CCS. (c) 2013 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.en_US
dc.identifier.doi10.1016/j.clinbiochem.2013.06.029en_US
dc.identifier.endpage1243en_US
dc.identifier.issn0009-9120en_US
dc.identifier.issue13-14en_US
dc.identifier.pmid23850849en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1239en_US
dc.identifier.urihttps://dx.doi.org/10.1016/j.clinbiochem.2013.06.029
dc.identifier.urihttps://hdl.handle.net/20.500.12395/29549
dc.identifier.volume46en_US
dc.identifier.wosWOS:000323857300013en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPERGAMON-ELSEVIER SCIENCE LTDen_US
dc.relation.ispartofCLINICAL BIOCHEMISTRYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectAnthracyclinesen_US
dc.subjectCardiotoxicityen_US
dc.subjectChildhood cancer survivorsen_US
dc.titleGrowth-differentiation factor-15 and tissue doppler imaging in detection of asymptomatic anthracycline cardiomyopathy in childhood cancer survivorsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu